Improving patient medication adherence Qorus-NTT DATA Innovation in Insurance Awards 2025

iPill addresses the lack of medication adherence as an FDA Class II breakthrough designated product. The enduser dispenser pharmacy and enduser prescribing physician have endless rules and regulations to follow when prescribing opioids, but the final user patient has no rules or regulations at home and can easily misuse, divert, actually overdose on the opioid they are prescribed.

75% of patients don’t take their prescribed medications correctly which results in 125,000 deaths annually and $290 billion per year in additional healthcare expenditures because of higher rates of hospital admissions, suboptimal health outcomes, and higher morbidity/mortality for chronic conditions.   With opioids, opioid use disorder (OUD) and overdose death can occur.  In 2023, there were 110,000 opioid overdose deaths at a cost of $1.5 trillion in medical expenses, unemployment, homelessness and crime.   We have medications to treat OUD and reduce opioid overdose deaths by 50% but only 11% of patients can get these medications due to significant barriers to access care, including lack of transportation, lack of childcare, lack of healthcare literacy, stigma, healthcare inequities, geographical disparities, health disparities, and reduction of social determinants of health.

Each overdose death costs $13.6 million. ($1.5 trillion/110,000)

iPill uses technology to bring holistic care to patients.

iPill monitors pills and patients by: * secure delivery, storage, and dispensing of medications to patients’ homes * biometric supported precise dispensing of medications only to the prescription holder at only the prescribed schedule. * remotely monitoring medication adherence to detect/remediate missed daily doses * notification alerts family, friends, and caregivers for missed doses, * destroying unused pills at 30 days and immediately if tampered * capturing vital signs via faceprint AI * delivering psychosocial support via telehealth